Pharmaceuticals News & Press Release Distribution

Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy

WUHAN, China and SAN DIEGO, Aug. 17, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary optic neuropathy caused byND1 ...

2023-08-17 21:00 2538

Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream for Treatment of Mild to Moderate Atopic Dermatitis

SHANGHAI, HANGZHOU, China and WILMINGTON, Del., Aug. 17, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, today announced the successful enrollment of the first patient in the phase 3 clinical study for MH004 Cream targeting mild to moderate a...

2023-08-17 19:00 5535

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

* Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐ Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including pat...

2023-08-17 18:00 5059

2023WCLC Oral Presentation | Molecular Analysis Validates the Effectiveness of Tumor Tissue-Based and Plasma ctDNA Testing in Identifying NSCLC Patients with EGFR Exon20ins Eligible for Treatment with Sunvozertinib

* A high concordance was observed between tumor tissue-based and plasma circulating tumor DNA (ctDNA) testing in detecting EGFR exon 20 insertion (Exon20ins) mutations. * Both tumor tissue-based and plasma ctDNA testing can be used to identify patients who may benefit from treatment with su...

2023-08-17 17:10 2954

Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...

2023-08-17 08:00 5152

Nippon Express (Ireland) Opens New Warehouse in Dublin, Beginning Operations July 1

TOKYO, Aug. 16, 2023 /PRNewswire/ -- Nippon Express (Ireland) Ltd. (hereafter "NX Ireland"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a new warehouse, "Contract Logistics Center," inDublin city, beginning its operations onJuly 1. Logo: https://kyodonewsprwire.jp/img/2023...

2023-08-16 14:00 2089

Nippon Express (Ireland) Opens New Warehouse in Dublin, Beginning Operations July 1

TOKYO, Aug. 16, 2023 /PRNewswire/ -- Nippon Express (Ireland) Ltd. (hereafter "NX Ireland"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a new warehouse, "Contract Logistics Center," inDublin city, beginning its operations onJuly 1. Logo: https://kyodonewsprwire.jp/img/2023...

2023-08-16 14:00 3327

Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines

'Fexuprazan,' Novel drug for Gastroesophageal Reflux Disease, starts its release inthe Philippines... The first case of overseas launch SEOUL, South Korea, Aug. 16, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Jeon Seng-ho, Lee Chang-jae) announced that 'Fuxuprazan' is officially launched i...

2023-08-16 13:00 4111

Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines

Charmacy Pharmaceutical Has Obtained the Provincial Capital Support

Future Expected Rapidly Growth HONG KONG, Aug. 16, 2023 /PRNewswire/ -- Charmacy Pharmaceutical Co., LTD. ( Charmacy Pharmaceutical, stock code: 2289.HK), as a leading private pharmaceutical distributor inSouth China, has been actively seeking strategic cooperation and resource complementary fro...

2023-08-16 09:00 5134

MedAlliance announces the completion of enrollment in SAVE Trial with SELUTION SLR for Treatment of AV Fistulas in Renal Dialysis Patients

GENEVA, Aug. 16, 2023 /PRNewswire/ -- MedAlliance has announced completion of patient enrollment in the SAVE Clinical Trial with the SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of failed AVF (arteriovenous fistulas) in renal dialysis patients. SELUTION SLR is a novel sirolimus-...

2023-08-16 08:00 3350

MedAlliance announces the completion of enrollment in SAVE Trial with SELUTION SLR for Treatment of AV Fistulas in Renal Dialysis Patients

Transcenta to Present Three Study Results at ESMO 2023

SUZHOU, China, Aug. 16, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it is going to ...

2023-08-16 08:00 3235

Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis

SAN DIEGO, SHANGHAI and SYDNEY, Aug. 15, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a glob...

2023-08-15 22:50 3147

CStone Pharmaceuticals Reports 2023 Interim Results and Updates

* The total revenue was RMB 261.5 million for the six months ended June 30, 2023. The sales of pharmaceutical products revenue was RMB 246.9 million, representing a growth rate of 53% compared to the same period last year. Commercial gross profit margin improved from 47% to 59%. * Healthy fin...

2023-08-15 22:33 6038

Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI)

SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase in...

2023-08-15 20:19 4752

OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors

NEW YORK, Aug. 15, 2023 /PRNewswire/ -- OnCusp Therapeutics, a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, announced today the clearance of its Investigational New Drug (IND) Applicatio...

2023-08-15 20:00 1760

TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan

Non-profit drug developer partners with leading manufacturer of medicine in Pakistan NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medici...

2023-08-14 21:30 2657

Kelun-Biotech announces that a Phase III clinical trial of core product SKB264 (MK-2870, TROP2-ADC) in patients with unresectable locally advanced, recurrent or metastatic TNBC who have failed second-line or above prior standard of care has met its primary endpoint

CHENGDU, China, Aug. 14, 2023 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. ("Kelun-Biotech", HKEX: 6990.HK) announced today that its innovative TROP2-ADC (SKB264, also known as MK-2870) met the primary endpoint in the randomized, controlled, open-label, multi-center Phase III ...

2023-08-14 12:50 6530

Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach

PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a$1M contract spanning two years (HHSF223018186...

2023-08-11 21:14 4726

Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer

SHANGHAI, Aug. 11, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical tr...

2023-08-11 17:00 4685

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...

2023-08-11 11:14 3063